An influence of a "tablet containing Haskap" on a symptomatic relief for a healthy person who is aware of eyestrain

An influence of a "tablet containing Haskap" on a symptomatic relief for a healthy person who is aware of eyestrain - An influence of a "tablet containing Haskap" on a symptomatic relief for a healthy person who is aware of eyestrain

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000026169

Enrollment

Registered

2017-04-30

Start date

2017-01-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy subjects

Interventions

4-week intake of the test food 4-week intake of the placebo food

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Age: 20 and over, below 40 2) Males and females with Japanese nationality 3) Persons who are aware of eyestrain on a daily basis 4) Persons who routinely plays videogames, uses a PC and/or a smartphone, or works on a VDT for at least 4 hours a day. 5) BMI under 30.0 6) Visual acuities of both eyes are 0.7 or higher (with or without vision correction devices) 7) Of those who are fully informed of the objective and contents of this study, have an ability to consent, and voluntarily wish to participate in this study with a clear understanding, persons who agree to participate in this study in writing.

Exclusion criteria

Exclusion criteria: 1) Currently in treatment with medication 2) Currently in dietary therapy and/or exercise therapy under medical supervision 3) Presence or previous history of a hepatic disorder, a severe kidney, endocrine, cardiovascular, gastrointestinal, pulmonary, hematological, or metabolic disorder, or a complication of these. 4) Those who are astigmatic 5) Those who uses a medical product, health food product, or a supplement claiming a positive effect on eyestrain or dry eye 6) Those who have an organic disease such as cataract, glaucoma, or strabismus 7) Presence or previous history of a mental disorder (depression, etc.) 8) Previous history of drug allergy or food allergy 9) Currently in treatment or previous history of drug addiction or drug abuse 10) Pregnant or nursing, or desired to become pregnant during the study 11) Participation in any other clinical study within 1 month or current participation in any other clinical study 12) Irregular work hours, such as night shifts 13) Difficulty in compliance with recording of various surveys 14) Determined by the investigator to be unsuitable for enrollment in this study

Design outcomes

Primary

Measure	Time frame
Near point (Accommodation ability test)	—

Secondary

Measure	Time frame
1. Equivalent spherical surface degree (Refractive power test) 2. Survey on subjective symptoms	—

Countries

Japan

Contacts

Public ContactHira Yoshitada

HUMA R&D CORP Clinical Development Division

hira@huma-c.co.jp81-3-3431-1260

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026

An influence of a &quot;tablet containing Haskap&quot; on a symptomatic relief for a healthy person who is aware of eyestrain